Revision as of 01:45, 15 October 2022

25 regimens on this page 25 variants on this page

Note: these are regimens specific to extranodal marginal zone lymphomas (EMZL) of mucosa-associated lymphoid tissue ("MALTomas"), please see the main MZL page for other regimens.

Guidelines

EGILS

2011: Ruskoné-Fourmestraux et al. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT

ESMO

2020: Zucca et al. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Older

2013: Dreyling et al. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma PubMed
2013: Zucca et al. Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Older

2009: Zucca et al. Gastric marginal zone lymphoma of MALT type: ESMO Clinical Recommendations for diagnosis, treatment and follow-up PubMed

NCCN

NCCN Guidelines - B-cell Lymphomas

Gastric MALT lymphoma, H. Pylori eradication therapy

Amoxicillin & PPI

Regimen

Study	Evidence
Bayerdörffer et al. 1995	Non-randomized

Antibiotic therapy

Amoxicillin 750 mg PO three times per day
Omeprazole (Prilosec) 40 mg PO three times per day

14-day course

References

Bayerdörffer E, Neubauer A, Rudolph B, Thiede C, Lehn N, Eidt S, Stolte M; MALT Lymphoma Study Group. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. Lancet. 1995 Jun 24;345(8965):1591-4. link to original article PubMed
1. Update: Neubauer A, Thiede C, Morgner A, Alpen B, Ritter M, Neubauer B, Wündisch T, Ehninger G, Stolte M, Bayerdörffer E. Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Natl Cancer Inst. 1997 Sep 17;89(18):1350-5. link to original article PubMed
2. Update: Wündisch T, Thiede C, Morgner A, Dempfle A, Günther A, Liu H, Ye H, Du MQ, Kim TD, Bayerdörffer E, Stolte M, Neubauer A. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol. 2005 Nov 1;23(31):8018-24. Epub 2005 Oct 3. link to original article contains dosing details in abstract PubMed

Amoxicillin, Clarithromycin, PPI, Bismuth

Regimen

Study	Evidence
Steinbach et al. 1999	Non-randomized

Antibiotic therapy

Amoxicillin 750 mg PO three times per day on days 1 to 21
Clarithromycin (Biaxin) 500 mg PO three times per day on days 1 to 21
Omeprazole (Prilosec) or Lansoprazole (Prevacid)
Bismuth subsalicylate (Pepto-Bismol)

8-week cycle for 2 cycles

References

Steinbach G, Ford R, Glober G, Sample D, Hagemeister FB, Lynch PM, McLaughlin PW, Rodriguez MA, Romaguera JE, Sarris AH, Younes A, Luthra R, Manning JT, Johnson CM, Lahoti S, Shen Y, Lee JE, Winn RJ, Genta RM, Graham DY, Cabanillas FF. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue: an uncontrolled trial. Ann Intern Med. 1999 Jul 20;131(2):88-95. link to original article contains dosing details in abstract PubMed

Ampicillin, Metronidazole, Bismuth

Regimen

Study	Evidence
Wotherspoon et al. 1993	Pilot

Antibiotic therapy

References

Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni M, Isaacson PG. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet. 1993 Sep 4;342(8871):575-7. link to original article PubMed

Ampicillin & PPI

Regimen

Study	Evidence
Wotherspoon et al. 1993	Pilot

Antibiotic therapy

References

Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni M, Isaacson PG. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet. 1993 Sep 4;342(8871):575-7. link to original article PubMed

Clarithromycin, Metronidzole, PPI

Regimen

Study	Evidence
Bayerdörffer et al. 1995	Non-randomized

Note: This was second-line treatment.

Antibiotic therapy

Clarithromycin (Biaxin) 250 mg PO twice per day
Metronidazole (Flagyl) 400 mg PO three times per day
Omeprazole (Prilosec) 40 mg PO twice per day

10-day course

References

Bayerdörffer E, Neubauer A, Rudolph B, Thiede C, Lehn N, Eidt S, Stolte M; MALT Lymphoma Study Group. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. Lancet. 1995 Jun 24;345(8965):1591-4. link to original article PubMed
1. Update: Neubauer A, Thiede C, Morgner A, Alpen B, Ritter M, Neubauer B, Wündisch T, Ehninger G, Stolte M, Bayerdörffer E. Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Natl Cancer Inst. 1997 Sep 17;89(18):1350-5. link to original article PubMed
2. Update: Wündisch T, Thiede C, Morgner A, Dempfle A, Günther A, Liu H, Ye H, Du MQ, Kim TD, Bayerdörffer E, Stolte M, Neubauer A. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol. 2005 Nov 1;23(31):8018-24. Epub 2005 Oct 3. link to original article contains dosing details in manuscript PubMed

Clarithromycin, Tetracycline, PPI, Bismuth

Regimen

Study	Evidence
Steinbach et al. 1999	Non-randomized

Antibiotic therapy

Clarithromycin (Biaxin) 500 mg PO three times per day on days 1 to 21
Tetracycline (Sumycin) 500 mg PO four times per day on days 1 to 21
Omeprazole (Prilosec) or Lansoprazole (Prevacid)
Bismuth subsalicylate (Pepto-Bismol)

8-week cycle for 2 cycles

References

Steinbach G, Ford R, Glober G, Sample D, Hagemeister FB, Lynch PM, McLaughlin PW, Rodriguez MA, Romaguera JE, Sarris AH, Younes A, Luthra R, Manning JT, Johnson CM, Lahoti S, Shen Y, Lee JE, Winn RJ, Genta RM, Graham DY, Cabanillas FF. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue: an uncontrolled trial. Ann Intern Med. 1999 Jul 20;131(2):88-95. link to original article contains dosing details in abstract PubMed

Metronidazole, Tetracycline, PPI, Bismuth

Regimen

Study	Evidence
Steinbach et al. 1999	Non-randomized

Antibiotic therapy

Metronidazole (Flagyl) 500 mg PO three times per day on days 1 to 21
Tetracycline (Sumycin) 500 mg PO four times per day on days 1 to 21
Omeprazole (Prilosec) or Lansoprazole (Prevacid)
Bismuth subsalicylate (Pepto-Bismol)

8-week cycle for 2 cycles

References

Steinbach G, Ford R, Glober G, Sample D, Hagemeister FB, Lynch PM, McLaughlin PW, Rodriguez MA, Romaguera JE, Sarris AH, Younes A, Luthra R, Manning JT, Johnson CM, Lahoti S, Shen Y, Lee JE, Winn RJ, Genta RM, Graham DY, Cabanillas FF. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue: an uncontrolled trial. Ann Intern Med. 1999 Jul 20;131(2):88-95. link to original article contains dosing details in abstract PubMed

Ocular adenexal MALT lymphoma, antibiotic therapy

Doxycycline monotherapy

Regimen

Study	Evidence
Ferreri et al. 2006	Phase 2, <20 patients in this subgroup
Ferreri et al. 2012 (IELSG 27)	Phase 2

Note: This treatment was intended for patients with ocular adnexal marginal zone lymphoma (OAMZL), given the association with Chlamydia psittaci.

Antibiotic therapy

Doxycycline 100 mg PO twice per day

3-week course

References

Ferreri AJ, Ponzoni M, Guidoboni M, Resti AG, Politi LS, Cortelazzo S, Demeter J, Zallio F, Palmas A, Muti G, Dognini GP, Pasini E, Lettini AA, Sacchetti F, De Conciliis C, Doglioni C, Dolcetti R. Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial. J Natl Cancer Inst. 2006 Oct 4;98(19):1375-82. link to original article contains dosing details in manuscript PubMed
IELSG 27: Ferreri AJ, Govi S, Pasini E, Mappa S, Bertoni F, Zaja F, Montalbán C, Stelitano C, Cabrera ME, Giordano Resti A, Politi LS, Doglioni C, Cavalli F, Zucca E, Ponzoni M, Dolcetti R. Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. J Clin Oncol. 2012 Aug 20;30(24):2988-94. Epub 2012 Jul 16. Erratum in: J Clin Oncol. 2012 Nov 1;30(31):3903. link to original article contains dosing details in manuscript PubMed NCT01010295

Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, first-line therapy

Note: This implies chemotherapy-naive. Some patients in the following studies, especially those with gastric MALT, received H. pylori eradication therapy or radiation prior to chemotherapy.

Bortezomib monotherapy

Regimen

Study	Years of enrollment	Evidence
Troch et al. 2009 (Velcade-MALT-Lymphoma)	NR	Phase 2

Targeted therapy

Bortezomib (Velcade) 1.5 mg/m² IV bolus once per day on days 1, 4, 8, 11

Supportive therapy

5-HT3 antagonist IV immediately before Bortezomib (Velcade)
500 mL NS after Bortezomib (Velcade)

21-day cycle for up to 8 cycles

References

Velcade-MALT-Lymphoma: Troch M, Jonak C, Müllauer L, Püspök A, Formanek M, Hauff W, Zielinski CC, Chott A, Raderer M. A phase II study of bortezomib in patients with MALT lymphoma. Haematologica. 2009 May;94(5):738-42. Epub 2009 Mar 31. link to original article contains dosing details in manuscript link to PMC article PubMed NCT00373906

Bendamustine & Rituximab (BR)

BR: Bendamustine, Rituximab

Regimen

Study	Years of enrollment	Evidence	Comparator	Comparative Efficacy
Salar et al. 2014 (GELTAMO MALT2008-01)	2009-2011	Phase 2

Note: treatment in MALT2008-01 was response adapted; patients with CR after 3 cycles received a total of 4 cycles, whereas patients with PR after 3 cycles received a total of 6 cycles.

Chemotherapy

Bendamustine 90 mg/m² IV once per day on days 1 & 2

Targeted therapy

Rituximab (Rituxan) 375 mg/m² IV once on day 1

Supportive therapy

Antiemetics, antipyretics, and antibiotics according to local standard of care
Prophylactic use of G-CSF allowed according ASCO guidelines (2006)

28-day cycle for up to 8 cycles (see note)

References

GELTAMO MALT2008-01: Salar A, Domingo-Domenech E, Panizo C, Nicolás C, Bargay J, Muntañola A, Canales M, Bello JL, Sancho JM, Tomás JF, Rodríguez MJ, Peñalver FJ, Grande C, Sánchez-Blanco JJ, Palomera L, Arranz R, Conde E, García M, García JF, Caballero D, Montalbán C; Grupo Español de Linfomas/Trasplante de Médula Ósea (GELTAMO). First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2014 Dec;1(3):e104-11. Epub 2014 Nov 19. link to original article contains dosing details in abstract PubMed NCT01015248
1. Update: Salar A, Domingo-Domenech E, Panizo C, Nicolás C, Bargay J, Muntañola A, Canales M, Bello JL, Sancho JM, Tomás JF, Rodríguez MJ, Peñalver J, Grande C, Sánchez-Blanco JJ, Palomera L, Arranz R, Conde E, García M, García JF, Caballero D, Montalbán C. Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma. Blood. 2017 Oct 12;130(15):1772-1774. Epub 2017 Aug 11. link to original article PubMed

Chlorambucil monotherapy

Regimen

Study	Years of enrollment	Evidence	Comparator	Comparative Efficacy
Zucca et al. 2013 (IELSG-19)	2003-2005	Phase 3 (E-de-esc)	1. Chlorambucil & Rituximab	Seems to have inferior PFS¹
Zucca et al. 2013 (IELSG-19)	2003-2005	Phase 3 (E-de-esc)	2. Rituximab	Did not meet primary endpoint of EFS¹

¹Reported efficacy is based on the 2017 update.

Chemotherapy

Chlorambucil (Leukeran) 6 mg/m² PO once per day

6-week course

Subsequent treatment

Patients with SD or better: Chlorambucil consolidation

References

IELSG-19: Zucca E, Conconi A, Laszlo D, López-Guillermo A, Bouabdallah R, Coiffier B, Sebban C, Jardin F, Vitolo U, Morschhauser F, Pileri SA, Copie-Bergman C, Campo E, Jack A, Floriani I, Johnson P, Martelli M, Cavalli F, Martinelli G, Thieblemont C. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study. J Clin Oncol. 2013 Feb 10;31(5):565-72. Epub 2013 Jan 7. link to original article contains dosing details in manuscript PubMed NCT00210353
1. Update: Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, Martelli M, Pettengell R, Salles G, Sebban C, Guillermo AL, Pinotti G, Devizzi L, Morschhauser F, Tilly H, Torri V, Hohaus S, Ferreri AJM, Zachée P, Bosly A, Haioun C, Stelitano C, Bellei M, Ponzoni M, Moreau A, Jack A, Campo E, Mazzucchelli L, Cavalli F, Johnson P, Thieblemont C. Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy. J Clin Oncol. 2017 Jun 10;35(17):1905-1912. Epub 2017 Mar 29. link to original article PubMed

Chlorambucil & Rituximab (RClb)

Regimen

Study	Years of enrollment	Evidence	Comparator	Comparative Efficacy
Zucca et al. 2013 (IELSG-19)	2003-2005	Phase 3 (E-esc)	1. Chlorambucil 2. Rituximab	Seems to have superior PFS¹ (HR 0.62, 95% CI 0.42-0.93)

¹Reported efficacy is based on the 2017 update.

Chemotherapy

Chlorambucil (Leukeran) 6 mg/m² PO once per day

Targeted therapy

Rituximab (Rituxan) 375 mg/m² IV once per day on days 1, 8, 15, 22

6-week course

Subsequent treatment

Patients with SD or better: Chlorambucil & rituximab consolidation

References

IELSG-19: Zucca E, Conconi A, Laszlo D, López-Guillermo A, Bouabdallah R, Coiffier B, Sebban C, Jardin F, Vitolo U, Morschhauser F, Pileri SA, Copie-Bergman C, Campo E, Jack A, Floriani I, Johnson P, Martelli M, Cavalli F, Martinelli G, Thieblemont C. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study. J Clin Oncol. 2013 Feb 10;31(5):565-72. Epub 2013 Jan 7. link to original article contains dosing details in manuscript PubMed NCT00210353
1. Update: Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, Martelli M, Pettengell R, Salles G, Sebban C, Guillermo AL, Pinotti G, Devizzi L, Morschhauser F, Tilly H, Torri V, Hohaus S, Ferreri AJM, Zachée P, Bosly A, Haioun C, Stelitano C, Bellei M, Ponzoni M, Moreau A, Jack A, Campo E, Mazzucchelli L, Cavalli F, Johnson P, Thieblemont C. Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy. J Clin Oncol. 2017 Jun 10;35(17):1905-1912. Epub 2017 Mar 29. link to original article PubMed

Cladribine monotherapy

Regimen

Study	Evidence
Jäger et al. 2002	Phase 2

Chemotherapy

Cladribine (Leustatin) 0.12 mg/kg IV over 2 hours once per day on days 1 to 5

28-day cycle for 4 to 6 cycles

Dose modifications

"In case of a persisting nadir of the WBC count less than or equal to 4.0 × 10⁹/L (or ANC less than or equal to 1500/uL) and/or the platelets less than or equal to 100 × 10⁹/L, the next treatment cycle was delayed by 1 week until achieving normal values and then treatment was administered at a reduced dose of 0.1 mg/kg body weight."

References

Jäger G, Neumeister P, Brezinschek R, Hinterleitner T, Fiebiger W, Penz M, Neumann HJ, Mlineritsch B, DeSantis M, Quehenberger F, Chott A, Beham-Schmid C, Höfler G, Linkesch W, Raderer M. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study. J Clin Oncol. 2002 Sep 15;20(18):3872-7. link to original article contains dosing details in manuscript PubMed

Cladribine & Rituximab

Regimen

Study	Years of enrollment	Evidence
Troch et al. 2012 (AGMT MALT)	2008-2010	Phase 2

Chemotherapy

Cladribine (Leustatin) 0.1 mg/kg SC once per day on days 1 to 4

Targeted therapy

Rituximab (Rituxan) 375 mg/m² IV once on day 1

Supportive therapy

Acetaminophen (Tylenol) 1000 mg PO once on day 1, prior to Rituximab (Rituxan)
Antihistamine IV once on day 1, prior to Rituximab (Rituxan)
One of the following:
- Ondansetron (Zofran) IV once per day on days 1 to 4, prior to Cladribine (Leustatin)
- Tropisetron (Navoban) IV once per day on days 1 to 4, prior to Cladribine (Leustatin)

21-day cycle for up to 6 cycles

References

AGMT MALT: Troch M, Kiesewetter B, Willenbacher W, Willenbacher E, Zebisch A, Linkesch W, Fridrik M, Müllauer L, Greil R, Raderer M. Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie. Haematologica. 2013 Feb;98(2):264-8. Epub 2012 Sep 14. link to original article contains dosing details in manuscript link to PMC article PubMed NCT00656812

Fludarabine and Rituximab (FR)

FR: Fludarabine & Rituximab

Regimen

Study	Evidence	Efficacy
Salar et al. 2009	Phase 2	ORR: 100%

Chemotherapy

Fludarabine (Fludara) 25 mg/m² IV (or 40 mg/m² PO) once per day on days 1 to 5
- Patients with gastric lymphoma received the cycle 1 dose intravenously to guarantee drug absorption
- Patients greater than 70 years old: same dose, but only once per day on days 1 to 3

Targeted therapy

Rituximab (Rituxan) 375 mg/m² IV once on day 1

Supportive therapy

Trimethoprim/Sulfamethoxazole prophylaxis (dose/schedule not listed) per physician preference
No routine antiviral prophylaxis or G-CSF use

28-day cycle for 4 to 6 cycles

References

Salar A, Domingo-Domenech E, Estany C, Canales MA, Gallardo F, Servitje O, Fraile G, Montalbán C. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type. Cancer. 2009 Nov 15;115(22):5210-7. link to orginal article contains dosing details in manuscript PubMed

Lenalidomide monotherapy

Regimen

Study	Evidence
Kiesewetter et al. 2012 (LEN-MALT)	Phase 2, <20 patients reported

Targeted therapy

Lenalidomide (Revlimid) 25 mg PO once per day on days 1 to 21

Supportive therapy

Aspirin 100 mg PO once per day

28-day cycle for up to 6 cycles

References

LEN-MALT: Kiesewetter B, Troch M, Dolak W, Müllauer L, Lukas J, Zielinski CC, Raderer M. A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma). Haematologica. 2013 Mar;98(3):353-6. Epub 2012 Aug 16. link to orginal article contains dosing details in manuscript link to PMC article PubMed NCT00923663

Lenalidomide & Rituximab (R²)

Regimen

Study	Evidence
Kiesewetter et al. 2016 (AGMT MALT-2)	Phase 2

Targeted therapy

Lenalidomide (Revlimid) 20 mg PO once per day on days 1 to 21
Rituximab (Rituxan) 375 mg/m² IV once on day 1

28-day cycle for up to 8 to 12 cycles

References

AGMT MALT-2: Kiesewetter B, Willenbacher E, Willenbacher W, Egle A, Neumeister P, Voskova D, Mayerhoefer ME, Simonitsch-Klupp I, Melchardt T, Greil R, Raderer M; AGMT Investigators. A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma. Blood. 2017 Jan 19;129(3):383-385. Epub 2016 Nov 22. link to original article contains dosing details in manuscript PubMed NCT01611259

MCP

MCP: Mitoxantrone, Chlorambucil, Prednisone

Regimen

Study	Evidence
Wöhrer et al. 2003	Retrospective

Note: the chlorambucil dose is written in the reference as "3 x 3 mg/m²"; total dose per day is 9 mg/m².

Chemotherapy

Mitoxantrone (Novantrone) 8 mg/m² IV once per day on days 1 & 2
Chlorambucil (Leukeran) 3 mg/m² PO three times per day on days 1 to 5

Glucocorticoid therapy

Prednisone (Sterapred) 25 mg/m² PO once per day on days 1 to 5

28-day cycle for up to 8 cycles

References

Retrospective: Wöhrer S, Drach J, Hejna M, Scheithauer W, Dirisamer A, Püspök A, Chott A, Raderer M. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP). Ann Oncol. 2003 Dec;14(12):1758-61. link to orginal article contains dosing details in manuscript PubMed

Rituximab monotherapy

Regimen

Study	Years of enrollment	Evidence	Comparator	Comparative Efficacy
Conconi et al. 2003 (IELSG 6)	2000-2001	Phase 2
Martinelli et al. 2005	NR	Phase 2
Zucca et al. 2013 (IELSG-19)	2003-2005	Phase 3 (E-switch-ooc)	1. Chlorambucil	Did not meet primary endpoint of EFS
Zucca et al. 2013 (IELSG-19)	2003-2005	Phase 3 (E-switch-ooc)	2. Chlorambucil & Rituximab	Seems to have inferior PFS

Targeted therapy

Rituximab (Rituxan) 375 mg/m² IV once per day on days 1, 8, 15, 22

Supportive therapy

Acetaminophen (Tylenol) 650 mg PO once per day on days 1, 8, 15, 22; 30 minutes prior to Rituximab (Rituxan)
Diphenhydramine (Benadryl) 50 mg PO once per day on days 1, 8, 15, 22; 30 minutes prior to Rituximab (Rituxan)

4-week course

References

Conconi A, Martinelli G, Thiéblemont C, Ferreri AJ, Devizzi L, Peccatori F, Ponzoni M, Pedrinis E, Dell'Oro S, Pruneri G, Filipazzi V, Dietrich PY, Gianni AM, Coiffier B, Cavalli F, Zucca E. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003 Oct 15;102(8):2741-5. link to orginal article contains dosing details in manuscript PubMed content property of HemOnc.org
Martinelli G, Laszlo D, Ferreri AJ, Pruneri G, Ponzoni M, Conconi A, Crosta C, Pedrinis E, Bertoni F, Calabrese L, Zucca E. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol. 2005 Mar 20;23(9):1979-83. link to original article contains dosing details in manuscript PubMed
IELSG-19: Zucca E, Conconi A, Laszlo D, López-Guillermo A, Bouabdallah R, Coiffier B, Sebban C, Jardin F, Vitolo U, Morschhauser F, Pileri SA, Copie-Bergman C, Campo E, Jack A, Floriani I, Johnson P, Martelli M, Cavalli F, Martinelli G, Thieblemont C. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study. J Clin Oncol. 2013 Feb 10;31(5):565-72. Epub 2013 Jan 7. link to original article contains dosing details in manuscript PubMed NCT00210353
1. Update: Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, Martelli M, Pettengell R, Salles G, Sebban C, Guillermo AL, Pinotti G, Devizzi L, Morschhauser F, Tilly H, Torri V, Hohaus S, Ferreri AJM, Zachée P, Bosly A, Haioun C, Stelitano C, Bellei M, Ponzoni M, Moreau A, Jack A, Campo E, Mazzucchelli L, Cavalli F, Johnson P, Thieblemont C. Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy. J Clin Oncol. 2017 Jun 10;35(17):1905-1912. Epub 2017 Mar 29. link to original article PubMed

Consolidation after first-line therapy

Chlorambucil monotherapy

Regimen

Study	Evidence
Zucca et al. 2013 (IELSG-19)	Non-randomized portion of RCT

Preceding treatment

Chlorambucil induction

Chemotherapy

Chlorambucil (Leukeran) 6 mg/m² PO once per day on days 1 to 14

28-day cycle for up to 4 cycles

References

IELSG-19: Zucca E, Conconi A, Laszlo D, López-Guillermo A, Bouabdallah R, Coiffier B, Sebban C, Jardin F, Vitolo U, Morschhauser F, Pileri SA, Copie-Bergman C, Campo E, Jack A, Floriani I, Johnson P, Martelli M, Cavalli F, Martinelli G, Thieblemont C. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study. J Clin Oncol. 2013 Feb 10;31(5):565-72. Epub 2013 Jan 7. link to original article contains dosing details in manuscript PubMed NCT00210353
1. Update: Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, Martelli M, Pettengell R, Salles G, Sebban C, Guillermo AL, Pinotti G, Devizzi L, Morschhauser F, Tilly H, Torri V, Hohaus S, Ferreri AJM, Zachée P, Bosly A, Haioun C, Stelitano C, Bellei M, Ponzoni M, Moreau A, Jack A, Campo E, Mazzucchelli L, Cavalli F, Johnson P, Thieblemont C. Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy. J Clin Oncol. 2017 Jun 10;35(17):1905-1912. Epub 2017 Mar 29. link to original article PubMed

Chlorambucil & Rituximab (RClb)

Regimen

Study	Evidence
Zucca et al. 2013 (IELSG-19)	Non-randomized portion of RCT

Preceding treatment

Chlorambucil & Rituximab induction

Chemotherapy

Chlorambucil (Leukeran) 6 mg/m² PO once per day on days 1 to 14

Targeted therapy

Rituximab (Rituxan) 375 mg/m² IV once on day 1

28-day cycle for up to 4 cycles

References

IELSG-19: Zucca E, Conconi A, Laszlo D, López-Guillermo A, Bouabdallah R, Coiffier B, Sebban C, Jardin F, Vitolo U, Morschhauser F, Pileri SA, Copie-Bergman C, Campo E, Jack A, Floriani I, Johnson P, Martelli M, Cavalli F, Martinelli G, Thieblemont C. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study. J Clin Oncol. 2013 Feb 10;31(5):565-72. Epub 2013 Jan 7. link to original article contains dosing details in manuscript PubMed NCT00210353
1. Update: Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, Martelli M, Pettengell R, Salles G, Sebban C, Guillermo AL, Pinotti G, Devizzi L, Morschhauser F, Tilly H, Torri V, Hohaus S, Ferreri AJM, Zachée P, Bosly A, Haioun C, Stelitano C, Bellei M, Ponzoni M, Moreau A, Jack A, Campo E, Mazzucchelli L, Cavalli F, Johnson P, Thieblemont C. Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy. J Clin Oncol. 2017 Jun 10;35(17):1905-1912. Epub 2017 Mar 29. link to original article PubMed

Observation

Regimen

Study	Years of enrollment	Evidence	Comparator	Comparative Efficacy
Hancock et al. 2008 (LY03)	1995-2001	Phase 3 (C)	Chlorambucil	Did not meet primary endpoint of RR

No further treatment.

Preceding treatment

H. pylori eradication therapy

References

LY03: Hancock BW, Qian W, Linch D, Delchier JC, Smith P, Jakupovic I, Burton C, Souhami R, Wotherspoon A, Copie-Bergman C, Capella C, Traulle C, Levy M, Cortelazzo S, Ferreri AJ, Ambrosetti A, Pinotti G, Martinelli G, Vitolo U, Cavalli F, Gisselbrecht C, Zucca E. Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial. Br J Haematol. 2009 Feb;144(3):367-75. Epub 2008 Nov 22. link to original article link to PMC article PubMed NCT00003617

Relapsed or refractory, randomized data

Rituximab monotherapy

Regimen

Study	Years of enrollment	Evidence	Comparator	Comparative Efficacy
Conconi et al. 2003 (IELSG 6)	2000-2001	Phase 2
Martinelli et al. 2005	NR	Phase 2

Targeted therapy

Rituximab (Rituxan) 375 mg/m² IV once per day on days 1, 8, 15, 22

28-day course

References

IELSG 6: Conconi A, Martinelli G, Thiéblemont C, Ferreri AJ, Devizzi L, Peccatori F, Ponzoni M, Pedrinis E, Dell'Oro S, Pruneri G, Filipazzi V, Dietrich PY, Gianni AM, Coiffier B, Cavalli F, Zucca E. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003 Oct 15;102(8):2741-5. link to orginal article contains dosing details in abstract PubMed
Martinelli G, Laszlo D, Ferreri AJ, Pruneri G, Ponzoni M, Conconi A, Crosta C, Pedrinis E, Bertoni F, Calabrese L, Zucca E. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol. 2005 Mar 20;23(9):1979-83. link to original article contains dosing details in abstract PubMed

Relapsed or refractory, non-randomized or retrospective data

Bortezomib monotherapy

Regimen variant #1, 1.3 mg/m²

Study	Years of enrollment	Evidence
Conconi et al. 2011 (IELSG 25A)	2005-2009	Phase 2

Targeted therapy

Bortezomib (Velcade) 1.3 mg/m² IV once per day on days 1, 4, 8, 11

Supportive therapy

No routine growth factors, antibiotic, or antiviral prophylaxis was given

21-day cycle for up to 6 cycles

Regimen variant #2, 1.5 mg/m²

Study	Years of enrollment	Evidence
Troch et al. 2009 (Velcade-MALT-Lymphoma)	NR	Phase 2, <20 pts

Targeted therapy

Bortezomib (Velcade) 1.5 mg/m² IV bolus once per day on days 1, 4, 8, 11

Supportive therapy

5-HT3 antagonist IV immediately before Bortezomib (Velcade)
500 mL NS after Bortezomib (Velcade)

21-day cycle for up to 8 cycles

References

Velcade-MALT-Lymphoma: Troch M, Jonak C, Müllauer L, Püspök A, Formanek M, Hauff W, Zielinski CC, Chott A, Raderer M. A phase II study of bortezomib in patients with MALT lymphoma. Haematologica. 2009 May;94(5):738-42. Epub 2009 Mar 31. link to original article contains dosing details in manuscript link to PMC article PubMed NCT00373906
IELSG 25A: Conconi A, Martinelli G, Lopez-Guillermo A, Zinzani PL, Ferreri AJ, Rigacci L, Devizzi L, Vitolo U, Luminari S, Cavalli F, Zucca E; International Extranodal Lymphoma Study Group. Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG). Ann Oncol. 2011 Mar;22(3):689-95. link to original article contains dosing details in manuscript PubMed NCT00210327

Cladribine & Rituximab

Regimen

Study	Years of enrollment	Evidence
Troch et al. 2012 (AGMT MALT)	2008-2010	Phase 2, <20 patients reported

Chemotherapy

Cladribine (Leustatin) 0.1 mg/kg SC once per day on days 1 to 4

Targeted therapy

Rituximab (Rituxan) 375 mg/m² IV once on day 1

Supportive therapy

Acetaminophen (Tylenol) 1000 mg PO once on day 1, prior to Rituximab (Rituxan)
Antihistamine IV once on day 1, prior to Rituximab (Rituxan)
One of the following:
- Ondansetron (Zofran) IV once per day on days 1 to 4, prior to Cladribine (Leustatin)
- Tropisetron (Navoban) IV once per day on days 1 to 4, prior to Cladribine (Leustatin)

21-day cycle for up to 6 cycles

References

AGMT MALT: Troch M, Kiesewetter B, Willenbacher W, Willenbacher E, Zebisch A, Linkesch W, Fridrik M, Müllauer L, Greil R, Raderer M. Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie. Haematologica. 2013 Feb;98(2):264-8. Epub 2012 Sep 14. link to original article contains dosing details in manuscript link to PMC article PubMed NCT00656812

Clarithromycin monotherapy

Regimen

Study	Evidence
Ferreri et al. 2015 (HD-K)	Phase 2

Antibiotic therapy

Clarithromycin (Biaxin) 2000 mg PO once per day on days 1 to 14

21-day cycle for 4 cycles

References

HD-K: Ferreri AJ, Sassone M, Kiesewetter B, Govi S, Scarfò L, Donadoni G, Raderer M. High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial. Ann Oncol. 2015 Aug;26(8):1760-5. Epub 2015 May 1. link to original article contains dosing details in manuscript PubMed NCT01516606

Lenalidomide monotherapy

Regimen

Study	Evidence
Kiesewetter et al. 2012 (LEN-MALT)	Phase 2, <20 patients reported

Targeted therapy

Lenalidomide (Revlimid) 25 mg PO once per day on days 1 to 21

Supportive therapy

Aspirin 100 mg PO once per day

28-day cycle for up to 6 cycles

References

LEN-MALT: Kiesewetter B, Troch M, Dolak W, Müllauer L, Lukas J, Zielinski CC, Raderer M. A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma). Haematologica. 2013 Mar;98(3):353-6. Epub 2012 Aug 16. link to orginal article contains dosing details in manuscript link to PMC article PubMed NCT00923663

Prognosis

MALT-IPI (2017)

Risk factors

Stage III or IV
Age older than 70 years
LDH greater than the upper limit of normal

Calculation

Low risk: zero risk factors present
Intermediate risk: one risk factor present
High risk: two or more risk factors present

References

Thieblemont C, Cascione L, Conconi A, Kiesewetter B, Raderer M, Gaidano G, Martelli M, Laszlo D, Coiffier B, Lopez Guillermo A, Torri V, Cavalli F, Johnson PW, Zucca E. A MALT lymphoma prognostic index. Blood. 2017 Sep 21;130(12):1409-1417. Epub 2017 Jul 18. link to original article PubMed

Response criteria

NCI Sponsored International Working Group Criteria (1999)

Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999 Apr;17(4):1244. Review. Erratum in: J Clin Oncol 2000 Jun;18(11):2351. link to original article PubMed

@@ Line 10: / Line 10: @@
 |}
 <big>'''Note: these are regimens specific to extranodal marginal zone lymphomas (EMZL) of mucosa-associated lymphoid tissue ("MALTomas"), please see the [[Marginal zone lymphoma|main MZL page]] for other regimens.'''</big>
 {{TOC limit|limit=3}}
 =Guidelines=
@@ Line 20: / Line 19: @@
 *'''2013:''' Dreyling et al. [https://doi.org/10.1093/annonc/mds643 ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma] [https://pubmed.ncbi.nlm.nih.gov/23425945 PubMed]
 *'''2013:''' Zucca et al. [https://www.esmo.org/Guidelines/Haematological-Malignancies/Gastric-Marginal-Zone-Lymphoma-of-MALT-Type Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up]
 ===Older===
 *'''2009:''' Zucca et al. [https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdp146 Gastric marginal zone lymphoma of MALT type: ESMO Clinical Recommendations for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/19454427 PubMed]
 ==[https://www.nccn.org/ NCCN]==
 *[https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf NCCN Guidelines - B-cell Lymphomas]
 =Gastric MALT lymphoma, H. Pylori eradication therapy=
 ==Amoxicillin & PPI {{#subobject:69pnz5|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:6a2ui9|Variant=1}}===
 {| class="wikitable" style="width: 40%; text-align:center;"
@@ Line 39: / Line 35: @@
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Antibiotic therapy====
 *[[Amoxicillin]] 750 mg PO three times per day
 *[[Omeprazole (Prilosec)]] 40 mg PO three times per day
 '''14-day course'''
+</div></div>
 ===References===
 # Bayerdörffer E, Neubauer A, Rudolph B, Thiede C, Lehn N, Eidt S, Stolte M; MALT Lymphoma Study Group. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. Lancet. 1995 Jun 24;345(8965):1591-4. [https://doi.org/10.1016/S0140-6736(95)90113-2 link to original article] [https://pubmed.ncbi.nlm.nih.gov/7783535 PubMed]
 ## '''Update:''' Neubauer A, Thiede C, Morgner A, Alpen B, Ritter M, Neubauer B, Wündisch T, Ehninger G, Stolte M, Bayerdörffer E. Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Natl Cancer Inst. 1997 Sep 17;89(18):1350-5. [https://doi.org/10.1093/jnci/89.18.1350 link to original article] [https://pubmed.ncbi.nlm.nih.gov/9308704 PubMed]
 ## '''Update:''' Wündisch T, Thiede C, Morgner A, Dempfle A, Günther A, Liu H, Ye H, Du MQ, Kim TD, Bayerdörffer E, Stolte M, Neubauer A. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol. 2005 Nov 1;23(31):8018-24. Epub 2005 Oct 3. [https://doi.org/10.1200/jco.2005.02.3903 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/16204012 PubMed]
 ==Amoxicillin, Clarithromycin, PPI, Bismuth {{#subobject:0hgba5|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:6iqsn1|Variant=1}}===
 {| class="wikitable" style="width: 40%; text-align:center;"
@@ Line 61: / Line 56: @@
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Antibiotic therapy====
 *[[Amoxicillin]] 750 mg PO three times per day on days 1 to 21
@@ Line 66: / Line 62: @@
 *[[Omeprazole (Prilosec)]] or [[Lansoprazole (Prevacid)]]
 *[[Bismuth subsalicylate (Pepto-Bismol)]]
 '''8-week cycle for 2 cycles'''
+</div></div>
 ===References===
 #Steinbach G, Ford R, Glober G, Sample D, Hagemeister FB, Lynch PM, McLaughlin PW, Rodriguez MA, Romaguera JE, Sarris AH, Younes A, Luthra R, Manning JT, Johnson CM, Lahoti S, Shen Y, Lee JE, Winn RJ, Genta RM, Graham DY, Cabanillas FF. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue: an uncontrolled trial. Ann Intern Med. 1999 Jul 20;131(2):88-95. [https://doi.org/10.7326/0003-4819-131-2-199907200-00003 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/10419446 PubMed]
 ==Ampicillin, Metronidazole, Bismuth {{#subobject:be3ef5|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:6a2469|Variant=1}}===
 {| class="wikitable" style="width: 40%; text-align:center;"
@@ Line 83: / Line 77: @@
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Antibiotic therapy====
 *[[Ampicillin]]
 *[[Metronidazole (Flagyl)]]
 *[[Tripotassium dicitratobismuthate (De-Noltab)]]
+</div></div>
 ===References===
 # Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni M, Isaacson PG. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet. 1993 Sep 4;342(8871):575-7. [https://doi.org/10.1016/0140-6736(93)91409-F link to original article] [https://pubmed.ncbi.nlm.nih.gov/8102719 PubMed]
 ==Ampicillin & PPI {{#subobject:be2nz5|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:6a2ui9|Variant=1}}===
 {| class="wikitable" style="width: 40%; text-align:center;"
@@ Line 102: / Line 96: @@
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Antibiotic therapy====
 *[[Ampicillin]]
 *[[Omeprazole (Prilosec)]]
+</div></div>
 ===References===
 # Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni M, Isaacson PG. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet. 1993 Sep 4;342(8871):575-7. [https://doi.org/10.1016/0140-6736(93)91409-F link to original article] [https://pubmed.ncbi.nlm.nih.gov/8102719 PubMed]
 ==Clarithromycin, Metronidzole, PPI {{#subobject:9ihjz5|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:6aubj1|Variant=1}}===
 {| class="wikitable" style="width: 40%; text-align:center;"
@@ Line 120: / Line 114: @@
 |-
 |}
-''This was second-line treatment.''
+''Note: This was second-line treatment.''
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Antibiotic therapy====
 *[[Clarithromycin (Biaxin)]] 250 mg PO twice per day
 *[[Metronidazole (Flagyl)]] 400 mg PO three times per day
 *[[Omeprazole (Prilosec)]] 40 mg PO twice per day
 '''10-day course'''
+</div></div>
 ===References===
 # Bayerdörffer E, Neubauer A, Rudolph B, Thiede C, Lehn N, Eidt S, Stolte M; MALT Lymphoma Study Group. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. Lancet. 1995 Jun 24;345(8965):1591-4. [https://doi.org/10.1016/S0140-6736(95)90113-2 link to original article] [https://pubmed.ncbi.nlm.nih.gov/7783535 PubMed]
 ## '''Update:''' Neubauer A, Thiede C, Morgner A, Alpen B, Ritter M, Neubauer B, Wündisch T, Ehninger G, Stolte M, Bayerdörffer E. Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Natl Cancer Inst. 1997 Sep 17;89(18):1350-5. [https://doi.org/10.1093/jnci/89.18.1350 link to original article] [https://pubmed.ncbi.nlm.nih.gov/9308704 PubMed]
 ## '''Update:''' Wündisch T, Thiede C, Morgner A, Dempfle A, Günther A, Liu H, Ye H, Du MQ, Kim TD, Bayerdörffer E, Stolte M, Neubauer A. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol. 2005 Nov 1;23(31):8018-24. Epub 2005 Oct 3. [https://doi.org/10.1200/jco.2005.02.3903 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/16204012 PubMed]
 ==Clarithromycin, Tetracycline, PPI, Bismuth {{#subobject:1ut7a5|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:0qobn1|Variant=1}}===
 {| class="wikitable" style="width: 40%; text-align:center;"
@@ Line 144: / Line 137: @@
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Antibiotic therapy====
 *[[Clarithromycin (Biaxin)]] 500 mg PO three times per day on days 1 to 21
@@ Line 149: / Line 143: @@
 *[[Omeprazole (Prilosec)]] or [[Lansoprazole (Prevacid)]]
 *[[Bismuth subsalicylate (Pepto-Bismol)]]
 '''8-week cycle for 2 cycles'''
+</div></div>
 ===References===
 #Steinbach G, Ford R, Glober G, Sample D, Hagemeister FB, Lynch PM, McLaughlin PW, Rodriguez MA, Romaguera JE, Sarris AH, Younes A, Luthra R, Manning JT, Johnson CM, Lahoti S, Shen Y, Lee JE, Winn RJ, Genta RM, Graham DY, Cabanillas FF. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue: an uncontrolled trial. Ann Intern Med. 1999 Jul 20;131(2):88-95. [https://doi.org/10.7326/0003-4819-131-2-199907200-00003 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/10419446 PubMed]
 ==Metronidazole, Tetracycline, PPI, Bismuth {{#subobject:9ogaz5|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:817ty1|Variant=1}}===
 {| class="wikitable" style="width: 40%; text-align:center;"
@@ Line 166: / Line 158: @@
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Antibiotic therapy====
 *[[Metronidazole (Flagyl)]] 500 mg PO three times per day on days 1 to 21
@@ Line 171: / Line 164: @@
 *[[Omeprazole (Prilosec)]] or [[Lansoprazole (Prevacid)]]
 *[[Bismuth subsalicylate (Pepto-Bismol)]]
 '''8-week cycle for 2 cycles'''
+</div></div>
 ===References===
 #Steinbach G, Ford R, Glober G, Sample D, Hagemeister FB, Lynch PM, McLaughlin PW, Rodriguez MA, Romaguera JE, Sarris AH, Younes A, Luthra R, Manning JT, Johnson CM, Lahoti S, Shen Y, Lee JE, Winn RJ, Genta RM, Graham DY, Cabanillas FF. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue: an uncontrolled trial. Ann Intern Med. 1999 Jul 20;131(2):88-95. [https://doi.org/10.7326/0003-4819-131-2-199907200-00003 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/10419446 PubMed]
 =Ocular adenexal MALT lymphoma, antibiotic therapy=
 ==Doxycycline monotherapy {{#subobject:342bb6|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:2b7c1c|Variant=1}}===
 {| class="wikitable" style="width: 40%; text-align:center;"
@@ Line 194: / Line 183: @@
 |-
 |}
-''This treatment was intended for patients with ocular adnexal marginal zone lymphoma (OAMZL), given the association with Chlamydia psittaci.''
+''Note: This treatment was intended for patients with ocular adnexal marginal zone lymphoma (OAMZL), given the association with Chlamydia psittaci.''
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Antibiotic therapy====
 *[[Doxycycline]] 100 mg PO twice per day
 '''3-week course'''
+</div></div>
 ===References===
 # Ferreri AJ, Ponzoni M, Guidoboni M, Resti AG, Politi LS, Cortelazzo S, Demeter J, Zallio F, Palmas A, Muti G, Dognini GP, Pasini E, Lettini AA, Sacchetti F, De Conciliis C, Doglioni C, Dolcetti R. Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial. J Natl Cancer Inst. 2006 Oct 4;98(19):1375-82. [http://jnci.oxfordjournals.org/content/98/19/1375.long link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/17018784 PubMed]
 # '''IELSG 27:''' Ferreri AJ, Govi S, Pasini E, Mappa S, Bertoni F, Zaja F, Montalbán C, Stelitano C, Cabrera ME, Giordano Resti A, Politi LS, Doglioni C, Cavalli F, Zucca E, Ponzoni M, Dolcetti R. Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. J Clin Oncol. 2012 Aug 20;30(24):2988-94. Epub 2012 Jul 16. Erratum in: J Clin Oncol. 2012 Nov 1;30(31):3903. [https://doi.org/10.1200/jco.2011.41.4466 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/22802315 PubMed] NCT01010295
 =Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, first-line therapy=
 ''Note: This implies chemotherapy-naive. Some patients in the following studies, especially those with gastric MALT, received H. pylori eradication therapy or radiation prior to chemotherapy.''
 ==Bortezomib monotherapy {{#subobject:8dbdb8|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:f62265|Variant=1}}===
 {| class="wikitable sortable" style="width: 60%; text-align:center;"
@@ Line 221: / Line 207: @@
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
 *[[Bortezomib (Velcade)]] 1.5 mg/m<sup>2</sup> IV bolus once per day on days 1, 4, 8, 11
 ====Supportive therapy====
 *[[:Category:Serotonin_5-HT3_antagonists|5-HT3 antagonist]] IV immediately before [[Bortezomib (Velcade)]]
 *500 mL NS after [[Bortezomib (Velcade)]]
 '''21-day cycle for up to 8 cycles'''
+</div></div>
 ===References===
 # '''Velcade-MALT-Lymphoma:''' Troch M, Jonak C, Müllauer L, Püspök A, Formanek M, Hauff W, Zielinski CC, Chott A, Raderer M. A phase II study of bortezomib in patients with MALT lymphoma. Haematologica. 2009 May;94(5):738-42. Epub 2009 Mar 31. [http://www.haematologica.org/content/94/5/738.long link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2675689/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/19336742 PubMed] NCT00373906
 ==Bendamustine & Rituximab (BR) {{#subobject:ac973d|Regimen=1}}==
 BR: '''<u>B</u>'''endamustine, '''<u>R</u>'''ituximab
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:7926ac|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
@@ Line 252: / Line 236: @@
 |}
 ''Note: treatment in MALT2008-01 was response adapted; patients with CR after 3 cycles received a total of 4 cycles, whereas patients with PR after 3 cycles received a total of 6 cycles.''
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Bendamustine]] 90 mg/m<sup>2</sup> IV once per day on days 1 & 2
 ====Targeted therapy====
 *[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
 ====Supportive therapy====
 *Antiemetics, antipyretics, and antibiotics according to local standard of care
 *Prophylactic use of [[:Category:Granulocyte colony-stimulating factors|G-CSF]] allowed according [https://doi.org/10.1200/jco.2006.06.4451 ASCO guidelines] (2006)
 '''28-day cycle for up to 8 cycles (see note)'''
+</div></div>
 ===References===
 # '''GELTAMO MALT2008-01:''' Salar A, Domingo-Domenech E, Panizo C, Nicolás C, Bargay J, Muntañola A, Canales M, Bello JL, Sancho JM, Tomás JF, Rodríguez MJ, Peñalver FJ, Grande C, Sánchez-Blanco JJ, Palomera L, Arranz R, Conde E, García M, García JF, Caballero D, Montalbán C; Grupo Español de Linfomas/Trasplante de Médula Ósea (GELTAMO). First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2014 Dec;1(3):e104-11. Epub 2014 Nov 19. [https://doi.org/10.1016/S2352-3026(14)00021-0 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/27029228 PubMed] NCT01015248
 ## '''Update:''' Salar A, Domingo-Domenech E, Panizo C, Nicolás C, Bargay J, Muntañola A, Canales M, Bello JL, Sancho JM, Tomás JF, Rodríguez MJ, Peñalver J, Grande C, Sánchez-Blanco JJ, Palomera L, Arranz R, Conde E, García M, García JF, Caballero D, Montalbán C. Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma. Blood. 2017 Oct 12;130(15):1772-1774. Epub 2017 Aug 11. [http://www.bloodjournal.org/content/130/15/1772.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/28801448 PubMed]
 ==Chlorambucil monotherapy {{#subobject:10e826|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:8fc8cb|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
@@ Line 288: / Line 270: @@
 |}
 ''<sup>1</sup>Reported efficacy is based on the 2017 update.''
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Chlorambucil (Leukeran)]] 6 mg/m<sup>2</sup> PO once per day
 '''6-week course'''
+</div>
+<div class="toccolours" style="background-color:#cbd5e7">
 ====Subsequent treatment====
 *Patients with SD or better: [[#Chlorambucil_monotherapy_2|Chlorambucil]] consolidation
+</div></div>
 ===References===
 # '''IELSG-19:''' Zucca E, Conconi A, Laszlo D, López-Guillermo A, Bouabdallah R, Coiffier B, Sebban C, Jardin F, Vitolo U, Morschhauser F, Pileri SA, Copie-Bergman C, Campo E, Jack A, Floriani I, Johnson P, Martelli M, Cavalli F, Martinelli G, Thieblemont C. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study. J Clin Oncol. 2013 Feb 10;31(5):565-72. Epub 2013 Jan 7. [https://doi.org/10.1200/jco.2011.40.6272 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/23295789 PubMed] NCT00210353
 <!-- # '''Abstract:''' E. Zucca, A. Conconi, G. Martinelli, A. Tucci, U. Vitolo, E. Russo, B. Coiffier, H. Ghesquieres, F. Morschhauser, R. Pettengell, G. Pinotti, L. Devizzi, R. Bouabdallah, C. Copie-Bergman, S. Pileri, A. Jack, E. Campo, A. Lopez-Guillermo, P. W. Johnson, C. Thieblemont. CHLORAMBUCIL PLUS RITUXIMAB PRODUCES BETTER EVENTFREE AND PROGRESSION-FREE SURVIVAL IN COMPARISON WITH CHLORAMBUCIL OR RITUXIMAB ALONE IN EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (MALT LYMPHOMA): FINAL RESULTS OF THE IELSG-19 STUDY. XII INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA Abstract 007 (2013). [http://www.ielsg.org/documents/ielsg19lug13.pdf link to abstract] -->
 ## '''Update:''' Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, Martelli M, Pettengell R, Salles G, Sebban C, Guillermo AL, Pinotti G, Devizzi L, Morschhauser F, Tilly H, Torri V, Hohaus S, Ferreri AJM, Zachée P, Bosly A, Haioun C, Stelitano C, Bellei M, Ponzoni M, Moreau A, Jack A, Campo E, Mazzucchelli L, Cavalli F, Johnson P, Thieblemont C. Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy. J Clin Oncol. 2017 Jun 10;35(17):1905-1912. Epub 2017 Mar 29. [https://doi.org/10.1200/JCO.2016.70.6994 link to original article] [https://pubmed.ncbi.nlm.nih.gov/28355112 PubMed]
 ==Chlorambucil & Rituximab (RClb) {{#subobject:346328|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:664c41|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
@@ Line 319: / Line 301: @@
 |}
 ''<sup>1</sup>Reported efficacy is based on the 2017 update.''
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Chlorambucil (Leukeran)]] 6 mg/m<sup>2</sup> PO once per day
 ====Targeted therapy====
 *[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22
 '''6-week course'''
+</div>
+<div class="toccolours" style="background-color:#cbd5e7">
 ====Subsequent treatment====
 *Patients with SD or better: [[#Chlorambucil_.26_Rituximab_.28RClb.29_2|Chlorambucil & rituximab]] consolidation
+</div></div>
 ===References===
 # '''IELSG-19:''' Zucca E, Conconi A, Laszlo D, López-Guillermo A, Bouabdallah R, Coiffier B, Sebban C, Jardin F, Vitolo U, Morschhauser F, Pileri SA, Copie-Bergman C, Campo E, Jack A, Floriani I, Johnson P, Martelli M, Cavalli F, Martinelli G, Thieblemont C. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study. J Clin Oncol. 2013 Feb 10;31(5):565-72. Epub 2013 Jan 7. [https://doi.org/10.1200/jco.2011.40.6272 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/23295789 PubMed] NCT00210353
 <!-- # '''Abstract:''' E. Zucca, A. Conconi, G. Martinelli, A. Tucci, U. Vitolo, E. Russo, B. Coiffier, H. Ghesquieres, F. Morschhauser, R. Pettengell, G. Pinotti, L. Devizzi, R. Bouabdallah, C. Copie-Bergman, S. Pileri, A. Jack, E. Campo, A. Lopez-Guillermo, P. W. Johnson, C. Thieblemont. CHLORAMBUCIL PLUS RITUXIMAB PRODUCES BETTER EVENTFREE AND PROGRESSION-FREE SURVIVAL IN COMPARISON WITH CHLORAMBUCIL OR RITUXIMAB ALONE IN EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (MALT LYMPHOMA): FINAL RESULTS OF THE IELSG-19 STUDY. XII INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA Abstract 007 (2013). [http://www.ielsg.org/documents/ielsg19lug13.pdf link to abstract] -->
 ## '''Update:''' Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, Martelli M, Pettengell R, Salles G, Sebban C, Guillermo AL, Pinotti G, Devizzi L, Morschhauser F, Tilly H, Torri V, Hohaus S, Ferreri AJM, Zachée P, Bosly A, Haioun C, Stelitano C, Bellei M, Ponzoni M, Moreau A, Jack A, Campo E, Mazzucchelli L, Cavalli F, Johnson P, Thieblemont C. Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy. J Clin Oncol. 2017 Jun 10;35(17):1905-1912. Epub 2017 Mar 29. [https://doi.org/10.1200/JCO.2016.70.6994 link to original article] [https://pubmed.ncbi.nlm.nih.gov/28355112 PubMed]
 ==Cladribine monotherapy {{#subobject:b1fc89|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:501943|Variant=1}}===
 {| class="wikitable" style="width: 40%; text-align:center;"
@@ Line 343: / Line 327: @@
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Cladribine (Leustatin)]] 0.12 mg/kg IV over 2 hours once per day on days 1 to 5
 '''28-day cycle for 4 to 6 cycles'''
 ====Dose modifications====
 *"In case of a persisting nadir of the WBC count less than or equal to 4.0 × 10<sup>9</sup>/L (or ANC less than or equal to 1500/uL) and/or the platelets less than or equal to 100 × 10<sup>9</sup>/L, the next treatment cycle was delayed by 1 week until achieving normal values and then treatment was administered at a reduced dose of 0.1 mg/kg body weight."
+</div></div>
 ===References===
 # Jäger G, Neumeister P, Brezinschek R, Hinterleitner T, Fiebiger W, Penz M, Neumann HJ, Mlineritsch B, DeSantis M, Quehenberger F, Chott A, Beham-Schmid C, Höfler G, Linkesch W, Raderer M. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study. J Clin Oncol. 2002 Sep 15;20(18):3872-7. [https://doi.org/10.1200/jco.2002.05.117 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/12228207 PubMed]
 ==Cladribine & Rituximab {{#subobject:3ac33|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:bd61ae|Variant=1}}===
 {| class="wikitable" style="width: 60%; text-align:center;"
@@ Line 368: / Line 349: @@
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Cladribine (Leustatin)]] 0.1 mg/kg SC once per day on days 1 to 4
 ====Targeted therapy====
 *[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
 ====Supportive therapy====
 *[[Acetaminophen (Tylenol)]] 1000 mg PO once on day 1, prior to [[Rituximab (Rituxan)]]
@@ Line 379: / Line 360: @@
 **[[Ondansetron (Zofran)]] IV once per day on days 1 to 4, prior to [[Cladribine (Leustatin)]]
 **[[Tropisetron (Navoban)]] IV once per day on days 1 to 4, prior to [[Cladribine (Leustatin)]]
 '''21-day cycle for up to 6 cycles'''
+</div></div>
 ===References===
 # '''AGMT MALT:''' Troch M, Kiesewetter B, Willenbacher W, Willenbacher E, Zebisch A, Linkesch W, Fridrik M, Müllauer L, Greil R, Raderer M. Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie. Haematologica. 2013 Feb;98(2):264-8. Epub 2012 Sep 14. [http://www.haematologica.org/content/98/2/264.long link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3561434/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/22983582 PubMed] NCT00656812
 ==Fludarabine and Rituximab (FR) {{#subobject:413f96|Regimen=1}}==
 FR: '''<u>F</u>'''ludarabine & '''<u>R</u>'''ituximab
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:8551bb|Variant=1}}===
 {| class="wikitable" style="width: 60%; text-align:center;"
@@ Line 399: / Line 378: @@
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Fludarabine (Fludara)]] 25 mg/m<sup>2</sup> IV (or 40 mg/m<sup>2</sup> PO) once per day on days 1 to 5
@@ Line 405: / Line 385: @@
 ====Targeted therapy====
 *[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
 ====Supportive therapy====
 *[[Trimethoprim-Sulfamethoxazole (Bactrim DS)|Trimethoprim/Sulfamethoxazole]] prophylaxis (dose/schedule not listed) per physician preference
 *No routine antiviral prophylaxis or G-CSF use
 '''28-day cycle for 4 to 6 cycles'''
+</div></div>
 ===References===
 # Salar A, Domingo-Domenech E, Estany C, Canales MA, Gallardo F, Servitje O, Fraile G, Montalbán C. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type. Cancer. 2009 Nov 15;115(22):5210-7. [https://doi.org/10.1002/cncr.24605 link to orginal article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/19672998 PubMed]
 ==Lenalidomide monotherapy {{#subobject:4f6ca7|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:43bad7|Variant=1}}===
 {| class="wikitable" style="width: 40%; text-align:center;"
@@ Line 427: / Line 403: @@
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
 *[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21
 ====Supportive therapy====
 *[[Aspirin]] 100 mg PO once per day
 '''28-day cycle for up to 6 cycles'''
+</div></div>
 ===References===
 # '''LEN-MALT:''' Kiesewetter B, Troch M, Dolak W, Müllauer L, Lukas J, Zielinski CC, Raderer M. A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma). Haematologica. 2013 Mar;98(3):353-6. Epub 2012 Aug 16. [http://www.haematologica.org/content/98/3/353.long link to orginal article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3659944/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/22899582 PubMed] NCT00923663
 ==Lenalidomide & Rituximab (R<sup>2</sup>) {{#subobject:c8fa86|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:38dadd|Variant=1}}===
 {| class="wikitable" style="width: 40%; text-align:center;"
 !style="width: 25%"|Study
@@ Line 451: / Line 423: @@
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
 *[[Lenalidomide (Revlimid)]] 20 mg PO once per day on days 1 to 21
 *[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
 '''28-day cycle for up to 8 to 12 cycles'''
+</div></div>
 ===References===
 # '''AGMT MALT-2:''' Kiesewetter B, Willenbacher E, Willenbacher W, Egle A, Neumeister P, Voskova D, Mayerhoefer ME, Simonitsch-Klupp I, Melchardt T, Greil R, Raderer M; AGMT Investigators. A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma. Blood. 2017 Jan 19;129(3):383-385. Epub 2016 Nov 22. [http://www.bloodjournal.org/content/129/3/383.long link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/27879257 PubMed] NCT01611259
 ==MCP {{#subobject:1cc3da|Regimen=1}}==
 MCP: '''<u>M</u>'''itoxantrone, '''<u>C</u>'''hlorambucil, '''<u>P</u>'''rednisone
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:2421bc|Variant=1}}===
 {| class="wikitable" style="width: 40%; text-align:center;"
@@ Line 474: / Line 444: @@
 |}
 ''Note: the chlorambucil dose is written in the reference as "3 x 3 mg/m<sup>2</sup>"; total dose per day is 9 mg/m<sup>2</sup>.''
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Mitoxantrone (Novantrone)]] 8 mg/m<sup>2</sup> IV once per day on days 1 & 2
@@ Line 479: / Line 450: @@
 ====Glucocorticoid therapy====
 *[[Prednisone (Sterapred)]] 25 mg/m<sup>2</sup> PO once per day on days 1 to 5
 '''28-day cycle for up to 8 cycles'''
+</div></div>
 ===References===
 # '''Retrospective:''' Wöhrer S, Drach J, Hejna M, Scheithauer W, Dirisamer A, Püspök A, Chott A, Raderer M. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP). Ann Oncol. 2003 Dec;14(12):1758-61. [https://doi.org/10.1093/annonc/mdg492 link to orginal article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/14630681 PubMed]
 ==Rituximab monotherapy {{#subobject:c82d07|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:c20616|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
@@ Line 518: / Line 486: @@
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
 *[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22
 ====Supportive therapy====
 *[[Acetaminophen (Tylenol)]] 650 mg PO once per day on days 1, 8, 15, 22; 30 minutes prior to [[Rituximab (Rituxan)]]
 *[[Diphenhydramine (Benadryl)]] 50 mg PO once per day on days 1, 8, 15, 22; 30 minutes prior to [[Rituximab (Rituxan)]]
 '''4-week course'''
+</div></div>
 ===References===
 # Conconi A, Martinelli G, Thiéblemont C, Ferreri AJ, Devizzi L, Peccatori F, Ponzoni M, Pedrinis E, Dell'Oro S, Pruneri G, Filipazzi V, Dietrich PY, Gianni AM, Coiffier B, Cavalli F, Zucca E. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003 Oct 15;102(8):2741-5. [http://www.bloodjournal.org/content/102/8/2741.long link to orginal article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/12842999 PubMed] content property of [http://hemonc.org HemOnc.org]
@@ Line 533: / Line 500: @@
 <!-- # '''Abstract:''' E. Zucca, A. Conconi, G. Martinelli, A. Tucci, U. Vitolo, E. Russo, B. Coiffier, H. Ghesquieres, F. Morschhauser, R. Pettengell, G. Pinotti, L. Devizzi, R. Bouabdallah, C. Copie-Bergman, S. Pileri, A. Jack, E. Campo, A. Lopez-Guillermo, P. W. Johnson, C. Thieblemont. CHLORAMBUCIL PLUS RITUXIMAB PRODUCES BETTER EVENTFREE AND PROGRESSION-FREE SURVIVAL IN COMPARISON WITH CHLORAMBUCIL OR RITUXIMAB ALONE IN EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (MALT LYMPHOMA): FINAL RESULTS OF THE IELSG-19 STUDY. XII INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA Abstract 007 (2013). [http://www.ielsg.org/documents/ielsg19lug13.pdf link to abstract] -->
 ## '''Update:''' Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, Martelli M, Pettengell R, Salles G, Sebban C, Guillermo AL, Pinotti G, Devizzi L, Morschhauser F, Tilly H, Torri V, Hohaus S, Ferreri AJM, Zachée P, Bosly A, Haioun C, Stelitano C, Bellei M, Ponzoni M, Moreau A, Jack A, Campo E, Mazzucchelli L, Cavalli F, Johnson P, Thieblemont C. Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy. J Clin Oncol. 2017 Jun 10;35(17):1905-1912. Epub 2017 Mar 29. [https://doi.org/10.1200/JCO.2016.70.6994 link to original article] [https://pubmed.ncbi.nlm.nih.gov/28355112 PubMed]
 =Consolidation after first-line therapy=
 ==Chlorambucil monotherapy {{#subobject:0c174d|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:9bb2aa|Variant=1}}===
 {| class="wikitable" style="width: 40%; text-align:center;"
@@ Line 548: / Line 512: @@
 |-
 |}
+<div class="toccolours" style="background-color:#cbd5e8">
 ====Preceding treatment====
 *[[#Chlorambucil_monotherapy|Chlorambucil]] induction
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Chlorambucil (Leukeran)]] 6 mg/m<sup>2</sup> PO once per day on days 1 to 14
 '''28-day cycle for up to 4 cycles'''
+</div></div>
 ===References===
 # '''IELSG-19:''' Zucca E, Conconi A, Laszlo D, López-Guillermo A, Bouabdallah R, Coiffier B, Sebban C, Jardin F, Vitolo U, Morschhauser F, Pileri SA, Copie-Bergman C, Campo E, Jack A, Floriani I, Johnson P, Martelli M, Cavalli F, Martinelli G, Thieblemont C. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study. J Clin Oncol. 2013 Feb 10;31(5):565-72. Epub 2013 Jan 7. [https://doi.org/10.1200/jco.2011.40.6272 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/23295789 PubMed] NCT00210353
 <!-- # '''Abstract:''' E. Zucca, A. Conconi, G. Martinelli, A. Tucci, U. Vitolo, E. Russo, B. Coiffier, H. Ghesquieres, F. Morschhauser, R. Pettengell, G. Pinotti, L. Devizzi, R. Bouabdallah, C. Copie-Bergman, S. Pileri, A. Jack, E. Campo, A. Lopez-Guillermo, P. W. Johnson, C. Thieblemont. CHLORAMBUCIL PLUS RITUXIMAB PRODUCES BETTER EVENTFREE AND PROGRESSION-FREE SURVIVAL IN COMPARISON WITH CHLORAMBUCIL OR RITUXIMAB ALONE IN EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (MALT LYMPHOMA): FINAL RESULTS OF THE IELSG-19 STUDY. XII INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA Abstract 007 (2013). [http://www.ielsg.org/documents/ielsg19lug13.pdf link to abstract] -->
 ## '''Update:''' Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, Martelli M, Pettengell R, Salles G, Sebban C, Guillermo AL, Pinotti G, Devizzi L, Morschhauser F, Tilly H, Torri V, Hohaus S, Ferreri AJM, Zachée P, Bosly A, Haioun C, Stelitano C, Bellei M, Ponzoni M, Moreau A, Jack A, Campo E, Mazzucchelli L, Cavalli F, Johnson P, Thieblemont C. Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy. J Clin Oncol. 2017 Jun 10;35(17):1905-1912. Epub 2017 Mar 29. [https://doi.org/10.1200/JCO.2016.70.6994 link to original article] [https://pubmed.ncbi.nlm.nih.gov/28355112 PubMed]
 ==Chlorambucil & Rituximab (RClb) {{#subobject:e72abc|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:594e34|Variant=1}}===
 {| class="wikitable" style="width: 40%; text-align:center;"
@@ Line 572: / Line 536: @@
 |-
 |}
+<div class="toccolours" style="background-color:#cbd5e8">
 ====Preceding treatment====
 *[[#Chlorambucil_.26_Rituximab_.28RClb.29|Chlorambucil & Rituximab]] induction
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Chlorambucil (Leukeran)]] 6 mg/m<sup>2</sup> PO once per day on days 1 to 14
 ====Targeted therapy====
 *[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
 '''28-day cycle for up to 4 cycles'''
+</div></div>
 ===References===
 # '''IELSG-19:''' Zucca E, Conconi A, Laszlo D, López-Guillermo A, Bouabdallah R, Coiffier B, Sebban C, Jardin F, Vitolo U, Morschhauser F, Pileri SA, Copie-Bergman C, Campo E, Jack A, Floriani I, Johnson P, Martelli M, Cavalli F, Martinelli G, Thieblemont C. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study. J Clin Oncol. 2013 Feb 10;31(5):565-72. Epub 2013 Jan 7. [https://doi.org/10.1200/jco.2011.40.6272 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/23295789 PubMed] NCT00210353
 <!-- # '''Abstract:''' E. Zucca, A. Conconi, G. Martinelli, A. Tucci, U. Vitolo, E. Russo, B. Coiffier, H. Ghesquieres, F. Morschhauser, R. Pettengell, G. Pinotti, L. Devizzi, R. Bouabdallah, C. Copie-Bergman, S. Pileri, A. Jack, E. Campo, A. Lopez-Guillermo, P. W. Johnson, C. Thieblemont. CHLORAMBUCIL PLUS RITUXIMAB PRODUCES BETTER EVENTFREE AND PROGRESSION-FREE SURVIVAL IN COMPARISON WITH CHLORAMBUCIL OR RITUXIMAB ALONE IN EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (MALT LYMPHOMA): FINAL RESULTS OF THE IELSG-19 STUDY. XII INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA Abstract 007 (2013). [http://www.ielsg.org/documents/ielsg19lug13.pdf link to abstract] -->
 ## '''Update:''' Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, Martelli M, Pettengell R, Salles G, Sebban C, Guillermo AL, Pinotti G, Devizzi L, Morschhauser F, Tilly H, Torri V, Hohaus S, Ferreri AJM, Zachée P, Bosly A, Haioun C, Stelitano C, Bellei M, Ponzoni M, Moreau A, Jack A, Campo E, Mazzucchelli L, Cavalli F, Johnson P, Thieblemont C. Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy. J Clin Oncol. 2017 Jun 10;35(17):1905-1912. Epub 2017 Mar 29. [https://doi.org/10.1200/JCO.2016.70.6994 link to original article] [https://pubmed.ncbi.nlm.nih.gov/28355112 PubMed]
 ==Observation==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
@@ Line 604: / Line 569: @@
 |}
 ''No further treatment.''
+<div class="toccolours" style="background-color:#cbd5e8">
 ====Preceding treatment====
 *[[#Helicobacter_pylori_eradication_therapy|H. pylori eradication therapy]]
+</div></div>
 ===References===
 # '''LY03:''' Hancock BW, Qian W, Linch D, Delchier JC, Smith P, Jakupovic I, Burton C, Souhami R, Wotherspoon A, Copie-Bergman C, Capella C, Traulle C, Levy M, Cortelazzo S, Ferreri AJ, Ambrosetti A, Pinotti G, Martinelli G, Vitolo U, Cavalli F, Gisselbrecht C, Zucca E. Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial. Br J Haematol. 2009 Feb;144(3):367-75. Epub 2008 Nov 22. [https://doi.org/full/10.1111/j.1365-2141.2008.07486.x link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2659366/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/19036078 PubMed] NCT00003617
 =Relapsed or refractory, randomized data=
 ==Rituximab monotherapy {{#subobject:29dc8b|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:73277c|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
@@ Line 635: / Line 599: @@
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
 *[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22
 '''28-day course'''
+</div></div>
 ===References===
 # '''IELSG 6:''' Conconi A, Martinelli G, Thiéblemont C, Ferreri AJ, Devizzi L, Peccatori F, Ponzoni M, Pedrinis E, Dell'Oro S, Pruneri G, Filipazzi V, Dietrich PY, Gianni AM, Coiffier B, Cavalli F, Zucca E. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003 Oct 15;102(8):2741-5. [http://www.bloodjournal.org/content/102/8/2741.long link to orginal article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/12842999 PubMed]
@@ Line 645: / Line 609: @@
 =Relapsed or refractory, non-randomized or retrospective data=
 ==Bortezomib monotherapy {{#subobject:448e81|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen variant #1, 1.3 mg/m<sup>2</sup> {{#subobject:583593|Variant=1}}===
 {| class="wikitable sortable" style="width: 60%; text-align:center;"
@@ Line 660: / Line 622: @@
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
 *[[Bortezomib (Velcade)]] 1.3 mg/m<sup>2</sup> IV once per day on days 1, 4, 8, 11
 ====Supportive therapy====
 *No routine growth factors, antibiotic, or antiviral prophylaxis was given
 '''21-day cycle for up to 6 cycles'''
+</div></div><br>
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen variant #2, 1.5 mg/m<sup>2</sup> {{#subobject:fd9bf5|Variant=1}}===
 {| class="wikitable sortable" style="width: 60%; text-align:center;"
@@ Line 679: / Line 641: @@
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
 *[[Bortezomib (Velcade)]] 1.5 mg/m<sup>2</sup> IV bolus once per day on days 1, 4, 8, 11
 ====Supportive therapy====
 *[[:Category:Serotonin_5-HT3_antagonists|5-HT3 antagonist]] IV immediately before [[Bortezomib (Velcade)]]
 *500 mL NS after [[Bortezomib (Velcade)]]
 '''21-day cycle for up to 8 cycles'''
+</div></div>
 ===References===
 # '''Velcade-MALT-Lymphoma:''' Troch M, Jonak C, Müllauer L, Püspök A, Formanek M, Hauff W, Zielinski CC, Chott A, Raderer M. A phase II study of bortezomib in patients with MALT lymphoma. Haematologica. 2009 May;94(5):738-42. Epub 2009 Mar 31. [http://www.haematologica.org/content/94/5/738.long link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2675689/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/19336742 PubMed] NCT00373906
 # '''IELSG 25A:''' Conconi A, Martinelli G, Lopez-Guillermo A, Zinzani PL, Ferreri AJ, Rigacci L, Devizzi L, Vitolo U, Luminari S, Cavalli F, Zucca E; International Extranodal Lymphoma Study Group. Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG). Ann Oncol. 2011 Mar;22(3):689-95. [https://doi.org/10.1093/annonc/mdq416 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/20810546 PubMed] NCT00210327
 ==Cladribine & Rituximab {{#subobject:bedbe7|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:d0a8c|Variant=1}}===
 {| class="wikitable" style="width: 60%; text-align:center;"
@@ Line 706: / Line 665: @@
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Cladribine (Leustatin)]] 0.1 mg/kg SC once per day on days 1 to 4
 ====Targeted therapy====
 *[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
 ====Supportive therapy====
 *[[Acetaminophen (Tylenol)]] 1000 mg PO once on day 1, prior to [[Rituximab (Rituxan)]]
@@ Line 717: / Line 676: @@
 **[[Ondansetron (Zofran)]] IV once per day on days 1 to 4, prior to [[Cladribine (Leustatin)]]
 **[[Tropisetron (Navoban)]] IV once per day on days 1 to 4, prior to [[Cladribine (Leustatin)]]
 '''21-day cycle for up to 6 cycles'''
+</div></div>
 ===References===
 # '''AGMT MALT:''' Troch M, Kiesewetter B, Willenbacher W, Willenbacher E, Zebisch A, Linkesch W, Fridrik M, Müllauer L, Greil R, Raderer M. Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie. Haematologica. 2013 Feb;98(2):264-8. Epub 2012 Sep 14. [http://www.haematologica.org/content/98/2/264.long link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3561434/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/22983582 PubMed] NCT00656812
 ==Clarithromycin monotherapy {{#subobject:bfabe7|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:a1a8c|Variant=1}}===
 {| class="wikitable" style="width: 40%; text-align:center;"
@@ Line 735: / Line 691: @@
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Antibiotic therapy====
 *[[Clarithromycin (Biaxin)]] 2000 mg PO once per day on days 1 to 14
 '''21-day cycle for 4 cycles'''
+</div></div>
 ===References===
 # '''HD-K:''' Ferreri AJ, Sassone M, Kiesewetter B, Govi S, Scarfò L, Donadoni G, Raderer M. High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial. Ann Oncol. 2015 Aug;26(8):1760-5. Epub 2015 May 1. [https://doi.org/10.1093/annonc/mdv214 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/25935794 PubMed] NCT01516606
 ==Lenalidomide monotherapy {{#subobject:2b1ccb|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:f1de78|Variant=1}}===
 {| class="wikitable" style="width: 40%; text-align:center;"
@@ Line 755: / Line 709: @@
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
 *[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21
 ====Supportive therapy====
 *[[Aspirin]] 100 mg PO once per day
 '''28-day cycle for up to 6 cycles'''
+</div></div>
 ===References===
 # '''LEN-MALT:''' Kiesewetter B, Troch M, Dolak W, Müllauer L, Lukas J, Zielinski CC, Raderer M. A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma). Haematologica. 2013 Mar;98(3):353-6. Epub 2012 Aug 16. [http://www.haematologica.org/content/98/3/353.long link to orginal article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3659944/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/22899582 PubMed] NCT00923663
 =Prognosis=
 ==MALT-IPI (2017)==
 ===Risk factors===
@@ Line 777: / Line 728: @@
 *'''Intermediate risk:''' one risk factor present
 *'''High risk:''' two or more risk factors present
+</div></div>
 ===References===
 # Thieblemont C, Cascione L, Conconi A, Kiesewetter B, Raderer M, Gaidano G, Martelli M, Laszlo D, Coiffier B, Lopez Guillermo A, Torri V, Cavalli F, Johnson PW, Zucca E. A MALT lymphoma prognostic index. Blood. 2017 Sep 21;130(12):1409-1417. Epub 2017 Jul 18. [http://www.bloodjournal.org/content/130/12/1409.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/28720586 PubMed]
 =Response criteria=
 ==NCI Sponsored International Working Group Criteria (1999)==
 # Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999 Apr;17(4):1244. Review. Erratum in: J Clin Oncol 2000 Jun;18(11):2351. [https://doi.org/10.1200/jco.1999.17.4.1244 link to original article] [https://pubmed.ncbi.nlm.nih.gov/10561185 PubMed]
 [[Category:MALT lymphoma regimens]]
 [[Category:Disease-specific pages]]
 [[Category:Marginal zone lymphomas]]
 [[Category:Non-Hodgkin lymphomas]]

Difference between revisions of "B-cell lymphoma of mucosa-associated lymphoid tissue"

Revision as of 01:45, 15 October 2022

Guidelines

EGILS

ESMO

Older

Older

NCCN

Gastric MALT lymphoma, H. Pylori eradication therapy

Amoxicillin & PPI

Regimen

Antibiotic therapy

References

Amoxicillin, Clarithromycin, PPI, Bismuth

Regimen

Antibiotic therapy

References

Ampicillin, Metronidazole, Bismuth

Regimen

Antibiotic therapy

References

Ampicillin & PPI

Regimen

Antibiotic therapy

References

Clarithromycin, Metronidzole, PPI

Regimen

Antibiotic therapy

References

Clarithromycin, Tetracycline, PPI, Bismuth

Regimen

Antibiotic therapy

References

Metronidazole, Tetracycline, PPI, Bismuth

Regimen

Antibiotic therapy

References

Ocular adenexal MALT lymphoma, antibiotic therapy

Doxycycline monotherapy

Regimen

Antibiotic therapy

References

Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, first-line therapy

Bortezomib monotherapy

Regimen

Targeted therapy

Supportive therapy

References

Bendamustine & Rituximab (BR)

Regimen

Chemotherapy

Targeted therapy

Supportive therapy

References

Chlorambucil monotherapy

Regimen

Chemotherapy

Subsequent treatment

References

Chlorambucil & Rituximab (RClb)

Regimen

Chemotherapy

Targeted therapy

Subsequent treatment

References

Cladribine monotherapy

Regimen

Chemotherapy

Dose modifications

References

Cladribine & Rituximab

Regimen

Chemotherapy

Targeted therapy

Supportive therapy

References

Fludarabine and Rituximab (FR)

Regimen

Chemotherapy

Targeted therapy

Lenalidomide & Rituximab (R²)

Regimen variant #1, 1.3 mg/m²

Regimen variant #2, 1.5 mg/m²